Tenaya Therapeutics (TNYA)
(Delayed Data from NSDQ)
$2.72 USD
+0.07 (2.64%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $2.73 +0.01 (0.37%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TNYA 2.72 +0.07(2.64%)
Will TNYA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TNYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TNYA
Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross?
Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet
TNYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's Why
Wall Street Analysts Believe Tenaya Therapeutics, Inc. (TNYA) Could Rally 217.58%: Here's is How to Trade
Tenaya Therapeutics, Inc. (TNYA) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for TNYA
Tenaya Therapeutics: A Buy Recommendation Based on Clinical Progress and Financial Fortitude
Buy Rating Affirmed for Tenaya Therapeutics: Strong Clinical Progress and Strategic Financial Positioning
TNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q2 2024
Piper Sandler Sticks to Its Buy Rating for Tenaya Therapeutics (TNYA)
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), GoodRx Holdings (GDRX) and Tenaya Therapeutics (TNYA)